Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

被引：0

作者：

Rodriguez-Otero, Paula ^{[1
]}

Joseph, Nisha ^{[2
]}

Kumar, Shaji ^{[3
]}

Leleu, Xavier ^{[4
]}

Manier, Salomon ^{[5
]}

Dimopoulos, Meletios ^{[6
]}

Mateos, Maria-Victoria ^{[7
]}

Oriol, Albert ^{[8
,9
]}

Bumma, Naresh ^{[10
]}

Gong, Weiying ^{[11
]}

Roy, Pourab ^{[11
]}

Lorenc, Karen Rodriguez ^{[11
]}

Kroog, Glenn ^{[11
]}

Sarkaria, Shawn ^{[11
]}

机构：

[1] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[3] Mayo Clin, Rochester, MN USA

[4] Hosp Mileterie, Poitiers, France

[5] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[6] Natl & Kapodistrian Univ Athens, Athens, Greece

[7] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[8] Catalan Inst Oncol, Hosp Germans Trias i Pujol, Badalona, Spain

[9] Josep Carreras Inst, Hosp Germans Trias i Pujol, Badalona, Spain

[10] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-046

引用

页码：S60 / S60

页数：1

共 50 条

[31] PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B KEYNOTE-013 STUDY
Ribrag, V.
Avigan, D. E.
Martinelli, G.
Green, D. J.
Wise-Draper, T.
Posada, J. G.
Vij, R.
Zhu, Y.
Farooqui, M. Z. H.
Marinello, P.
Siegel, D. S.
HAEMATOLOGICA, 2017, 102 : 114 - 114
[32] Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
Vogl, Dan T.
Raje, Noopur
Hari, Parameswaran
Jones, Simon S.
Supko, Jeffrey G.
Leone, Gina
Wheeler, Catherine
Orlowski, Robert Z.
Richardson, Paul G.
Lonial, Sagar
Tamang, David
Jagannath, Sundar
BLOOD, 2014, 124 (21)
[33] ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing
Baljevic, Muhamed
Magen, Hila
Searle, Emma
Jin, Ziyi
Strange, Elise
Svensson, Anders
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S163
[34] Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Lesokhin, Alexander
LeBlanc, Richard
Dimopoulos, Meletios A.
Capra, Marcelo
Carlo-Stella, Carmelo
Karlin, Lionel
Castilloux, Jean-Francois
Forsberg, Peter
Parmar, Gurdeep
Tosikyan, Axel
Pour, Ludek
Ribrag, Vincent
Ribolla, Rossella
Abdallah, Al-Ola
Le Roux, Nadia
Dong, Liyan
van de Velde, Helgi
Mayrargue, Laurent
Lepine, Lucie
Mace, Sandrine
Moreau, Philippe
CANCER MEDICINE, 2023, 12 (09): : 10254 - 10266
[35] CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel in relapsed/Refractory multiple myeloma
Madduri, Deepu
Berdeja, Jesus
Usmani, Saad
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam
Stewart, A. Keith
Hari, Parameswaran
Htut, Myo
O'Donnell, Elizabeth
Munshi, Nikhil
Avigan, David
Deol, Abhinav
Lesokhin, Alexander
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia
Olyslager, Yunsi
Banerjee, Arnob
Goldberg, Jenna
Schecter, Jordan
Jackson, Carolyn
Deraedt, William
Zhuang, Sen Hong
Infante, Jeffrey
Geng, Dong
Wu, Xiaoling
Carrasco-Alfonso, Marlene
Akram, Muhammad
Hossain, Farah
Rizvi, Syed
Fan, Frank
Jagannath, Sundar
Lin, Yi
Martin, Thomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 16 - 17
[36] An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
Moreau, Philippe
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
de la Rubia, Javier
Facon, Thierry
Comenzo, Raymond L.
Fay, Joseph W.
Qin, Xiang
Masterson, Tara
Schecter, Jordan
Ahmadi, Tahamtan
San Miguel, Jesus
BLOOD, 2014, 124 (21)
[37] Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study
Searle, Emma
Quach, Hang
Biran, Noa
Perrot, Aurore
Berdeja, Jesus G.
Dorritie, Kathleen
Van Elssen, Catharina
Touzeau, Cyrille
Anguille, Sebastien
Vishwamitra, Deeksha
Nguyen, Ashley
Ghosh, Debopriya
Shearin, Elizabeth
Mason, Gary E.
Renaud, Thomas
Matous, Jeffrey
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S550
[38] Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Gonsalves, Wilson I.
Kumar, Shaji
Perez, Gabriela
Saathoff, Stephanie
Wilson, Diana M.
Young, Anna
Ailawadhi, Sikander
BLOOD, 2021, 138
[39] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander
Raza, Muhammed
Acosta, Jorge
Mueller, Patrick Y.
O'Connell, Ashleigh
Yver, Anne
Lou, Carolyn
Finn, Gregory
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
[40] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Lesokhin, Alexander M.
Raza, Muhammed Saleem
Acosta, Jorge
Muller, Patrick
O'Connell, Ashleigh
Yver, Anne
Lou, Carolyn
Finn, Gregory
Service, Myeloma
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →